Metabolism Archives - Corcept Therapeutics

Miricorilant, a Selective Glucocorticoid Receptor Modulator, Reprograms Hepatic Gene Networks in Metabolic Dysfunction–Associated Steatohepatitis

November 7, 2025

Mayoral Monibas, et al. • 2025 • AASLD 2025

Effect of Hepatic Impairment on the Pharmacokinetics of Miricorilant: Results from a Phase 1, Open-Label, Adaptive-Design Study

May 12, 2025

Custodio et al. • 2025 • EASL 2025 Congress

MONARCH: a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH)

January 13, 2025

Alkhouri et al. • 2025 • MASH-TAG 2025 Congress

Metabolomic and Lipidomic Analysis of Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treated with the Selective Glucocorticoid Receptor Modulator Miricorilant

November 18, 2024

Kowdley et al. • 2024 • AASLD 2024 Congress

Pharmacokinetics of the Selective Glucocorticoid Receptor Modulator Miricorilant in Healthy Volunteers and Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

June 10, 2024

Custodio et al. • 2024 • EASL 2024 Congress

MONARCH: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH)

January 8, 2024

Alkhouri et al. • 2024 • NASH-TAG 2024 Congress

Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)

January 8, 2024

Alkhouri et al. • 2024 • NASH-TAG 2024 Congress

Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)

November 13, 2023

Alkhouri et al. • 2023 • AASLD 2023 Congress

Miricorilant, a selective GR modulator, induced a rapid and significant reduction in liver fat content in a randomized, placebo-controlled phase 2a study in patients with nonalcoholic steatohepatitis

January 28, 2023

Kowdley et al • 2021 • The Liver Meeting 2021 (American Association for the Study of Liver Diseases)

Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study

January 24, 2023

Hunt et al • 2021 • Journal of Clinical Psychopharmacology: August 6, 2021